Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [9]. Core Insights - The strategic investment in Yangshan Medical enhances the company's digital dental ecosystem by integrating "materials + equipment + services" in the dental implant sector [5]. - The launch of the new product 3DPro zir Ultra significantly reduces delivery time from 3 days to 24 hours while maintaining aesthetic compatibility, contributing to stable gross margins [6]. - Domestic rare earth regulations provide a competitive advantage in international markets by stabilizing the cost of yttrium, a key component in zirconia ceramics [7][8]. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are projected at 1.016 billion, 1.181 billion, and 1.371 billion yuan respectively, with corresponding EPS of 1.77, 2.30, and 2.87 yuan [9]. - The company is expected to maintain a gross margin of approximately 52.9% to 55.0% from 2024 to 2027, despite market pressures [11].

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [9]. Core Insights - The strategic investment in Yangshan Medical enhances the company's digital dental ecosystem by integrating "materials + equipment + services" in the dental implant sector [5]. - The launch of the new product 3DPro zir Ultra significantly reduces delivery time from 3 days to 24 hours while maintaining aesthetic compatibility, contributing to stable gross margins [6]. - Domestic rare earth regulations provide a competitive advantage in international markets by stabilizing the cost of yttrium oxide, essential for zirconia ceramic production [7][8]. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are projected at 1.016 billion, 1.181 billion, and 1.371 billion yuan respectively, with corresponding EPS of 1.77, 2.30, and 2.87 yuan [9][11]. - The company is expected to maintain a gross margin of approximately 52.9% to 55.0% over the forecast period [11].